Minerva Neurosciences, Inc. - Understand $nerv stock

$NERV Market Cap: $14.83 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$0.00

TTM

Gross Margin

Net Earnings

-$3.312M

TTM

Current Assets

$27.94M

Q3 2024

Current Liabilities

$4.483M

Q3 2024

Current Ratio

623.15%

Q3 2024

Total Assets

$42.81M

Q3 2024

Total Liabilities

$64.48M

Q3 2024

Book Value

-$21.67M

Q3 2024

Cash

$26.53M

Q3 2024

P/E

-4.477

Nov 29, 2024 EST

Free Cash Flow

-$5.995M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Revenue	$0.00	$0.00	$0.00	$41.18M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change			-100.0%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Revenue	$0.00	$0.00	$0.00	$41.18M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Selling, General & Admin	$10.41M	$10.58M	$13.33M	$17.29M	$17.74M	$16.84M	$10.91M	$9.750M	$7.580M	$11.96M	$2.450M	$1.030M	$530.0K
YoY Change	-1.59%	-20.59%	-22.92%	-2.54%	5.34%	54.35%	11.9%	28.63%	-36.62%	388.16%	137.86%	94.34%
% of Gross Profit
Research & Development	$12.71M	$14.65M	$32.04M	$22.04M	$58.12M	$34.89M	$30.26M	$20.44M	$18.53M	$42.91M	$708.5K	$550.0K	$590.0K
YoY Change	-13.27%	-54.28%	45.37%	-62.08%	66.6%	15.31%	48.02%	10.29%	-56.81%	5956.35%	28.82%	-6.78%
% of Gross Profit
Depreciation & Amortization	$30.98K	$8.510K	$0.00	$16.01K	$17.47K	$17.47K	$11.09K	$16.53K	$17.28K	$33.87K
YoY Change	264.04%		-100.0%	-8.34%	0.0%	57.45%	-32.89%	-4.32%	-48.99%
% of Gross Profit
Operating Expenses	$23.12M	$25.23M	$45.37M	$22.04M	$75.87M	$34.89M	$41.17M	$30.19M	$26.11M	$54.87M	$708.5K	$1.580M	$1.130M
YoY Change	-8.37%	-44.38%	105.84%	-70.95%	117.45%	-15.26%	36.37%	15.63%	-52.42%	7644.71%	-55.16%	39.82%
Operating Profit	-$23.12M	-$25.23M	-$45.37M	$1.847M	-$75.87M			-$30.19M	-$26.11M	-$54.87M
YoY Change	-8.37%	-44.38%	-2556.52%	-102.43%				15.63%	-52.42%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Interest Expense	$1.397M	$529.2K	-$16.33K	$90.00K	$1.430M	-$110.4K	-$614.3K	-$1.030M	-$1.053M	-$2.050M	-$90.00K	$0.00	$10.00K
YoY Change	164.01%	-3340.72%	-118.14%	-93.71%	-1394.73%	-82.02%	-40.35%	-2.22%	-48.62%	2177.48%		-100.0%
% of Operating Profit				4.87%
Other Income/Expense, Net	-$8.283M	-$7.407M	-$6.327M
YoY Change	11.83%	17.06%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Pretax Income	-$30.01M	-$32.11M	-$51.71M	$1.941M	-$74.44M	-$50.17M	-$40.90M	-$31.05M	-$27.08M	-$56.90M	-$3.260M	-$1.580M	-$1.120M
YoY Change	-6.55%	-37.91%	-2764.37%	-102.61%	48.37%	22.67%	31.74%	14.64%	-52.4%	1645.4%	106.33%	41.07%
Income Tax		$0.00	-$1.803M	$0.00	-$2.254M	$0.00	-$9.400M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
% Of Pretax Income				0.0%
Net Earnings	-$30.01M	-$32.11M	-$49.91M	$1.941M	-$72.18M	-$50.17M	-$31.52M	-$31.05M	-$27.08M	-$56.90M	-$3.260M	-$1.580M	-$1.120M
YoY Change	-6.55%	-35.66%	-2671.45%	-102.69%	43.87%	59.16%	1.54%	14.64%	-52.41%	1645.44%	106.33%	41.07%
Net Earnings / Revenue				4.71%
Basic Earnings Per Share	-$4.61	-$6.01	-$1.17	$0.05	-$1.85
Diluted Earnings Per Share	-$4.61	-$6.01	-$1.17	$0.05	-$1.85	-$1.293M	-$830.8K	-$985.4K	-$1.157M	-$4.473M	-$178.3K	-$86.43K	-$61.27K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Cash & Short-Term Investments	$40.91M	$36.09M	$60.76M	$25.40M	$45.90M	$88.00M	$128.2M	$83.00M	$32.20M	$18.50M	$1.800M	$200.0K	$200.0K
YoY Change	13.35%	-40.59%	139.19%	-44.66%	-47.84%	-31.36%	54.46%	157.76%	74.05%	927.78%	800.0%	0.0%
Cash & Equivalents	$40.91M	$36.09M	$60.76M	$25.40M	$21.40M	$50.20M	$26.10M	$83.00M	$14.30M	$18.50M	$1.800M	$200.0K	$200.0K
Short-Term Investments				$0.00	$24.40M	$37.80M	$102.1M	$0.00	$17.90M
Other Short-Term Assets	$1.090M	$4.065M	$1.446M	$2.100M	$1.300M	$2.000M	$1.400M	$900.0K	$1.300M	$800.0K	$0.00	$0.00	$0.00
YoY Change	-73.19%	181.07%	-31.13%	61.54%	-35.0%	42.86%	55.56%	-30.77%	62.5%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$42.00M	$40.16M	$62.20M	$27.40M	$47.10M	$90.00M	$129.5M	$83.90M	$33.50M	$19.30M	$1.800M	$200.0K	$200.0K
YoY Change	4.59%	-35.44%	127.01%	-41.83%	-47.67%	-30.5%	54.35%	150.45%	73.58%	972.22%	800.0%	0.0%
Property, Plant & Equipment	$10.88K	$16.33K	$0.00	$100.0K	$300.0K	$0.00	$100.0K	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	-33.37%		-100.0%	-66.67%		-100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments						$0.00	$5.000M
YoY Change						-100.0%
Other Assets			$0.00	$0.00	$0.00	$0.00	$0.00			$0.00	$400.0K	$0.00
YoY Change										-100.0%
Total Long-Term Assets	$14.90M	$14.93M	$14.92M	$30.20M	$30.40M	$49.10M	$54.20M	$49.00M	$49.10M	$49.20M	$27.40M	$0.00	$0.00
YoY Change	-0.21%	0.05%	-50.59%	-0.66%	-38.09%	-9.41%	10.61%	-0.2%	-0.2%	79.56%
Total Assets	$56.90M	$55.09M	$77.12M	$57.60M	$77.50M	$139.1M	$183.7M	$132.9M	$82.60M	$68.50M	$29.20M	$200.0K	$200.0K
YoY Change
Accounts Payable	$1.805M	$969.7K	$1.853M	$1.000M	$2.300M	$1.800M	$1.400M	$1.500M	$1.400M	$600.0K	$500.0K	$0.00
YoY Change	86.18%	-47.68%	85.32%	-56.52%	27.78%	28.57%	-6.67%	7.14%	133.33%	20.0%
Accrued Expenses	$1.535M	$407.9K	$965.7K	$2.200M	$4.300M	$1.800M	$1.400M	$3.400M	$2.500M	$2.900M	$800.0K	$200.0K	$100.0K
YoY Change	276.33%	-57.76%	-56.1%	-48.84%	138.89%	28.57%	-58.82%	36.0%	-13.79%	262.5%	300.0%	100.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$100.0K	$0.00	$0.00
YoY Change										-100.0%
Long-Term Debt Due						$0.00	$4.000M	$4.900M	$1.400M
YoY Change						-100.0%	-18.37%	250.0%
Total Short-Term Liabilities	$3.340M	$1.378M	$2.819M	$3.200M	$6.600M	$3.600M	$6.800M	$9.700M	$5.300M	$3.500M	$1.400M	$200.0K	$100.0K
YoY Change	142.48%	-51.13%	-11.91%	-51.52%	83.33%	-47.06%	-29.9%	83.02%	51.43%	150.0%	600.0%	100.0%
Long-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$3.800M	$8.500M	$0.00	$0.00	$0.00	$0.00
YoY Change							-100.0%	-55.29%
Other Long-Term Liabilities	$82.02M	$73.73M	$66.33M	$0.00	$41.30M	$41.20M	$41.20M		$0.00	$0.00			$0.00
YoY Change	11.23%	11.17%		-100.0%	0.24%	0.0%
Total Long-Term Liabilities	$82.02M	$73.73M	$66.33M	$0.00	$41.30M	$41.20M	$41.20M	$3.800M	$8.500M	$0.00	$0.00	$0.00	$0.00
YoY Change	11.23%	11.17%		-100.0%	0.24%	0.0%	984.21%	-55.29%
Total Liabilities	$85.36M	$75.11M	$69.15M	$5.000M	$49.70M	$48.90M	$52.10M	$27.00M	$27.30M	$17.00M	$9.000M	$200.0K	$100.0K
YoY Change	13.64%	8.63%	1282.93%	-89.94%	1.64%	-6.14%	92.96%	-1.1%	60.59%	88.89%	4400.0%	100.0%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019
Basic Shares Outstanding	6.506M	5.340M	42.72M	40.82M	39.01M
Diluted Shares Outstanding	6.506M	5.340M	42.72M	40.92M	39.01M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $14.826 Million

About Minerva Neurosciences, Inc.

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The company is headquartered in Waltham, Massachusetts and currently employs 9 full-time employees. The company went IPO on 2014-06-25. The company is engaged in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and have exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson's disease. The company has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of the major depressive disorder (MDD). Roluperidone is a compound that blocks serotonin, sigma, and a-adrenergic receptors that are involved in the regulation of mood, cognition, sleep, and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1), protein, for the treatment of Parkinson's disease and for other neurodegenerative disorders.

Industry: Pharmaceutical Preparations Peers: Applied Therapeutics, Inc. DYADIC INTERNATIONAL INC Quince Therapeutics, Inc. EXAGEN INC. Immunome Inc. Lantern Pharma Inc. MERRIMACK PHARMACEUTICALS INC Synaptogenix, Inc. SERA PROGNOSTICS, INC.